Zoetis Inc.
"Sector" = median of Healthcare across 84 companies
About Zoetis Inc.
AI-generatedZoetis Inc. is a global animal health company that discovers, develops, manufactures, and markets veterinary vaccines, medicines, diagnostics, and other products for livestock and companion animals. It was spun off from Pfizer in 2013 and is the largest pure-play animal health company in the world. Zoetis operates in over 45 countries and sells products in approximately 100 markets, focusing on preventing and treating diseases in animals.
Zoetis generates revenue through two main segments: Livestock (cattle, swine, poultry, fish) and Companion Animals (dogs, cats, horses). Its product portfolio includes vaccines, anti-infectives, parasiticides, and dermatology products. The company also offers diagnostic devices and genetic tests. Revenue is split roughly 60% from livestock and 40% from companion animals, with the U.S. accounting for about 55% of total sales. Zoetis invests heavily in R&D to develop new products and expand its pipeline.
Zoetis operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It competes with other animal health companies such as Elanco, Merck Animal Health, and Boehringer Ingelheim. Zoetis holds a leading market share in many categories, particularly in vaccines and parasiticides. Its strong brand recognition, extensive distribution network, and focus on innovation give it a competitive edge. The industry benefits from steady demand for animal protein and increasing pet ownership.
Zoetis’s customers include veterinarians, livestock producers, and pet owners. Its products are used by veterinary clinics, farms, and ranches worldwide. Key geographic markets are the United States, Europe, and emerging markets such as Brazil, China, and Australia. The company has a large sales force that directly markets to veterinarians and distributors. Zoetis also provides educational resources and technical support to its customers, strengthening loyalty and adoption of its products.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Financial highlights
Latest saved period: March 2026 · 2026-03-31
Dividend history
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Apr 20, 2026 | $0.53 | Jun 2, 2026 | Quarterly |
| Jan 20, 2026 | $0.53 | Mar 3, 2026 | Quarterly |
| Oct 31, 2025 | $0.50 | Dec 2, 2025 | Quarterly |
| Jul 18, 2025 | $0.50 | Sep 3, 2025 | Quarterly |
| Apr 21, 2025 | $0.50 | Jun 3, 2025 | Quarterly |
| Jan 21, 2025 | $0.50 | Mar 4, 2025 | Quarterly |
| Oct 31, 2024 | $0.43 | Dec 3, 2024 | Quarterly |
| Jul 18, 2024 | $0.43 | Sep 4, 2024 | Quarterly |
| Apr 18, 2024 | $0.43 | Jun 4, 2024 | Quarterly |
| Jan 18, 2024 | $0.43 | Mar 1, 2024 | Quarterly |
| Oct 31, 2023 | $0.38 | Dec 1, 2023 | Quarterly |
| Jul 20, 2023 | $0.38 | Sep 1, 2023 | Quarterly |
| Apr 20, 2023 | $0.38 | Jun 1, 2023 | Quarterly |
| Jan 19, 2023 | $0.38 | Mar 1, 2023 | Quarterly |
| Oct 31, 2022 | $0.33 | Dec 1, 2022 | Quarterly |
| Jul 20, 2022 | $0.33 | Sep 1, 2022 | Quarterly |
| Apr 20, 2022 | $0.33 | Jun 1, 2022 | Quarterly |
| Jan 19, 2022 | $0.33 | Mar 1, 2022 | Quarterly |
| Oct 28, 2021 | $0.25 | Dec 1, 2021 | Quarterly |
| Jul 20, 2021 | $0.25 | Sep 1, 2021 | Quarterly |
| Apr 20, 2021 | $0.25 | Jun 1, 2021 | Quarterly |
| Jan 19, 2021 | $0.25 | Mar 1, 2021 | Quarterly |
| Oct 20, 2020 | $0.20 | Dec 1, 2020 | Quarterly |
| Jul 16, 2020 | $0.20 | Sep 1, 2020 | Quarterly |
Revenue
↑ 46.1%Net Income
↑ 59.4%Free Cash Flow
↓ 16.4%Diluted EPS
↑ 10.1%Zoetis Inc. (ZTS) analysis
Wrqti brings Zoetis Inc. data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Stocks related to Zoetis Inc.
Companies in the Healthcare sector you can compare with Zoetis Inc.: